Lindus Health Unveils “All-in-One Dermatology CRO” Offering for Dermatology Clinical Trials
NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life...
Clinical Trial
Jennifer Stacey Joins PicnicHealth as Chief Delivery Officer
SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/ -- Today, PicnicHealth, a company dedicated to simplifying observational research, announced the appointment of Jennifer...
Luminopia Covered by Highmark Health for Treatment of Pediatric Amblyopia
Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the...
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter...
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company...
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year...
TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose...
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
Figure 1 Combination of dulaglutide (Trulicity®) and buntanetap improves memory and synaptic plasticity in AD mice (*p<0.05, **p<0.01). Figure 2...
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
19,000-square-foot facility reflects the company’s recent growth and continued commitment to the regionMORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) --...
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025...
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
A$4.4 million of valid applications received for the Share Purchase PlanIn conjunction with recently completed A$8.0 million institutional placement, total...
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in...
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life...
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL Responders) demonstrated significant...
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024...
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage...